title: Elbasvir/Grazoprevir.
abstract: Each month, subscribers toThe Formulary Monograph Servicereceive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation ofThe Formulary, Hospital Pharmacypublishes selected reviews in this column. For more information aboutThe Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The September 2016 monograph topics are barictinib, buprenorphine implants, sarilumab, sofosbuvir/velpatasvir, and cholera vaccine, live, oral. The Safey MUE is on sofosbuvir/velpatasvir.
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Cada
authors.forename: Anne P
authors.initials: AP
authors.lastname: Kim
authors.forename: Danial E
authors.initials: DE
authors.lastname: Baker